ArtGene Therapeutics is a partner company that holds an intellectual property license for the Neovasculgen drug and developments created outside the Russian Federation and the CIS. The company conducts preclinical and clinical trials, develops the ART-101 drug which is an improved version of Neovasculgen.
Partnership: University of Maryland
Recombinant plasmid DNA-based gene therapy drugs stimulate the formation and growth of collateral vessels. Indications: treatment of conditions that require the development of collateral circulation.
Lower Limb Ischemia
The action of the drug is fundamentally different from all known drugs for the treatment of chronic lower limb ischemia (CLI). This is the world’s first gene therapy drug based on the “therapeutic angiogenesis” mechanism (therapeutic vessel growth).
Neovasculgen stimulates the production of vascular endothelial growth factor VEGF-165, resulting in the growth of new microvasculature at the site of drug administration, which results in better blood supply to the ischemic area.
Clinically, patients show a more than 5-fold increase in pain-free walking distance (PFWD) and an improvement of such indicators as tissue oxygenation, ankle-brachial index, linear blood flow velocity.
The drug is included in the “List of Vital and Essential Drugs” and “National and Clinical Guidelines for CLI Treatment.”
Diabetic Foot Syndrome
Interstitial Cystitis
Androgenetic Alopecia
Peripheral Nerve Injuries